RxDoctor Payments Data

Amy Johnson

Family · Lynch Station, VANPI 1295160935

Payments from drug & device makers

$956in general payments, 2019–2025

Across 16 payments — averaging $59.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$162
  • Lundbeck LLC$121
  • Novo Nordisk$101
  • AbbVie$98
  • Argenx US, Inc.$88
  • Genentech USA, Inc.$87
  • plus $299 from 6 others

What the payments were for

  • Food & beverage$956100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$956 in reported general payments places this provider in the 70th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$117,286
Medicare patients
379
Services billed
2,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$124,036
OzempicSemaglutide106$122,965
XareltoRivaroxaban67$62,867
JanuviaSitagliptin Phosphate41$53,342
JardianceEmpagliflozin36$40,704
TrulicityDulaglutide39$38,492
FarxigaDapagliflozin Propanediol34$35,941
MounjaroTirzepatide28$31,738
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$21,959
Breo ElliptaFluticasone/Vilanterol46$18,549
MyrbetriqMirabegron18$17,727
Tresiba Flextouch U-200Insulin Degludec15$15,742
Tresiba Flextouch U-100Insulin Degludec13$6,454
Albuterol Sulfate HfaAlbuterol Sulfate162$4,443
Novolog FlexpenInsulin Aspart14$4,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$124,036109 claims
Novo NordiskOzempic$101$122,965106 claims
AstraZenecaFarxiga, Symbicort$162$40,18848 claims
AbbVieSynthroid$98$1,97627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,332 family providers in Virginia.

Other family in Lynch Station

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →